123 related articles for article (PubMed ID: 21805689)
1. Screening of hepatitis C virus inhibitors using genotype 1a HCV replicon cell lines.
Robinson M; Tian Y; Pagratis N; Delaney WE
Curr Protoc Microbiol; 2011 Aug; Chapter 17():Unit17.7. PubMed ID: 21805689
[TBL] [Abstract][Full Text] [Related]
2. Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.
Mondal R; Koev G; Pilot-Matias T; He Y; Ng T; Kati W; Molla A
Antiviral Res; 2009 Apr; 82(1):82-8. PubMed ID: 19174175
[TBL] [Abstract][Full Text] [Related]
3. Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.
Binder J; Tetangco S; Weinshank M; Maegley K; Lingardo L; Diehl W; Love R; Patick AK; Smith GJ
Antiviral Res; 2011 Aug; 91(2):102-11. PubMed ID: 21620899
[TBL] [Abstract][Full Text] [Related]
4. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
[TBL] [Abstract][Full Text] [Related]
5. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.
Qi X; Bae A; Liu S; Yang H; Sun SC; Harris J; Delaney W; Miller M; Mo H
Antiviral Res; 2009 Feb; 81(2):166-73. PubMed ID: 19063924
[TBL] [Abstract][Full Text] [Related]
6. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
Sheaffer AK; Lee MS; Hernandez D; Chaniewski S; Yu F; Falk P; Friborg J; Zhai G; McPhee F
Antivir Ther; 2011; 16(5):705-18. PubMed ID: 21817192
[TBL] [Abstract][Full Text] [Related]
7. Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a.
Robinson M; Yang H; Sun SC; Peng B; Tian Y; Pagratis N; Greenstein AE; Delaney WE
Antimicrob Agents Chemother; 2010 Aug; 54(8):3099-106. PubMed ID: 20516274
[TBL] [Abstract][Full Text] [Related]
8. A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors.
Vijgen L; Verbeeck J; Van Kerckhove B; Berke JM; Koletzki D; Fanning G; Lenz O
Methods Mol Biol; 2013; 1030():105-17. PubMed ID: 23821263
[TBL] [Abstract][Full Text] [Related]
9. Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system.
Bourne N; Pyles RB; Yi M; Veselenak RL; Davis MM; Lemon SM
Antiviral Res; 2005 Aug; 67(2):76-82. PubMed ID: 15927278
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening.
Hao W; Herlihy KJ; Zhang NJ; Fuhrman SA; Doan C; Patick AK; Duggal R
Antimicrob Agents Chemother; 2007 Jan; 51(1):95-102. PubMed ID: 17060518
[TBL] [Abstract][Full Text] [Related]
11. High-throughput screening of HCV RNA replication inhibitors by means of a reporter replicon system.
Hao W; Duggal R
Methods Mol Biol; 2009; 510():243-50. PubMed ID: 19009266
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.
Zhang N; Turpoff A; Zhang X; Huang S; Liu Y; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Pichardo J; Colacino J; Lahser F; Ingravallo P; Weetall M; Nomeir A; Karp GM
Bioorg Med Chem Lett; 2016 Jan; 26(2):594-601. PubMed ID: 26652483
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates.
Rajyaguru S; Yang H; Martin R; Miller MD; Mo H
Antiviral Res; 2013 Nov; 100(2):328-36. PubMed ID: 24013002
[TBL] [Abstract][Full Text] [Related]
14. Replication of a novel subgenomic HCV genotype 1a replicon expressing a puromycin resistance gene in Huh-7 cells.
Liang C; Rieder E; Hahm B; Jang SK; Paul A; Wimmer E
Virology; 2005 Mar; 333(1):41-53. PubMed ID: 15708591
[TBL] [Abstract][Full Text] [Related]
15. Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to anti-HCV reagents.
Nishimura G; Ikeda M; Mori K; Nakazawa T; Ariumi Y; Dansako H; Kato N
Antiviral Res; 2009 Apr; 82(1):42-50. PubMed ID: 19428594
[TBL] [Abstract][Full Text] [Related]
16. Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B.
Dufner-Beattie J; O'Guin A; O'Guin S; Briley A; Wang B; Balsarotti J; Roth R; Starkey G; Slomczynska U; Noueiry A; Olivo PD; Rice CM
Antimicrob Agents Chemother; 2014 Jun; 58(6):3399-410. PubMed ID: 24709254
[TBL] [Abstract][Full Text] [Related]
17. Development of a robust luciferase reporter 1b/2a hepatitis C virus (HCV) for characterization of early stage HCV life cycle inhibitors.
Chan K; Robinson M; Yang H; Cornew S; Delaney Iv WE
Antiviral Res; 2013 Apr; 98(1):85-92. PubMed ID: 23376631
[TBL] [Abstract][Full Text] [Related]
18. In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.
Voitenleitner C; Crosby R; Walker J; Remlinger K; Vamathevan J; Wang A; You S; Johnson J; Woldu E; Van Horn S; Horton J; Creech K; Shotwell JB; Hong Z; Hamatake R
Antimicrob Agents Chemother; 2013 Nov; 57(11):5216-24. PubMed ID: 23939896
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM
Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109
[TBL] [Abstract][Full Text] [Related]
20. Tricistronic hepatitis C virus subgenomic replicon expressing double transgenes.
Cheng X; Gao XC; Wang JP; Yang XY; Wang Y; Li BS; Kang FB; Li HJ; Nan YM; Sun DX
World J Gastroenterol; 2014 Dec; 20(48):18284-95. PubMed ID: 25561795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
